Latest news with #TenayaTherapeutics
Yahoo
3 days ago
- Business
- Yahoo
Tenaya Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference
SOUTH SAN FRANCISCO, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Faraz Ali, Tenaya's Chief Executive Officer, will participate in the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025 at 11:30 am ET. The live webcast of the fireside chat may be accessed from the Investors section of Tenaya's website. An archived replay will be available on the Tenaya website for approximately 30 days following the live event. About Tenaya TherapeuticsTenaya Therapeutics is a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver potentially curative therapies that address the underlying drivers of heart disease. Tenaya's pipeline includes clinical-stage candidates TN-201, a gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM) and TN-401, a gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC). Tenaya has employed a suite of integrated internal capabilities, including modality agnostic target validation, capsid engineering and manufacturing, to generate a portfolio of novel medicines based on genetic insights, including TN-301, a clinical-stage small molecule HDAC6 inhibitor for the potential treatment of heart failure and related cardio/muscular disease, and multiple early-stage programs in preclinical development aimed at the treatment of both rare genetic disorders and more prevalent heart conditions. For more information, visit Tenaya ContactsMichelle CorralVP, Corporate Communications and Investor RelationsIR@ InvestorsAnne-Marie FieldsPrecision AQ in to access your portfolio
Associated Press
13-05-2025
- Business
- Associated Press
Tenaya Therapeutics to Highlight Capsid Engineering, Gene Editing and Manufacturing Research at the ASGCT 28th Annual Meeting
SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it will present five abstracts at the upcoming American Society of Gene and Cell Therapy (ASGCT 2025) 28th Annual Meeting taking place May 13-17, 2025 in New Orleans, LA. The abstracts being presented at ASGCT 2025 capture the outcome of efforts to advance Tenaya's core capabilities in novel capsid engineering, identification, design and optimization of cardiomyocyte-targeting genetic medicines, and manufacturing of adeno-associated virus (AAV) gene therapies. Abstract highlights Details of Tenaya's ASGCT 2025 presentations are as follows: Tuesday, May 13, 2025 Poster Abstract Session - 6:00 pm – 7:30 pm Wednesday, May 14, 2025 Poster Abstract Session – 5:30 pm – 7:30 pm Following the conference, Tenaya's presentations will be available in the 'Our Science' section of the company's website. About Tenaya Therapeutics Tenaya Therapeutics is a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver potentially curative therapies that address the underlying drivers of heart disease. Tenaya employs a suite of integrated internal capabilities, including modality agnostic target validation, capsid engineering and manufacturing, to generate a portfolio of genetic medicines aimed at the treatment of both rare genetic disorders and more prevalent heart conditions. Tenaya's pipeline includes TN-201, a gene therapy for MYBPC3 -associated hypertrophic cardiomyopathy (HCM), TN-401, a gene therapy for PKP2 -associated arrhythmogenic right ventricular cardiomyopathy (ARVC), TN-301, a small molecule HDAC6 inhibitor intended for heart failure with preserved ejection fraction (HFpEF), and multiple early-stage programs in preclinical development. For more information, visit Forward-Looking Statements This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Words such as 'will,' 'potential,' 'may,' and similar expressions are intended to identify forward-looking statements. Such forward-looking statements include, among other things, the presentation of data covering Tenaya's capabilities in novel capsid engineering, identification, design and optimization of cardiomyocyte-targeting genetic medicines, and manufacturing of AAV gene therapies; the therapeutic potential of Tenaya's prime editing technology in a humanized RBM20 murine model of DCM; TN-501 as a potential treatment for PLN R14del-associated DCM; the commercial potential of Tenaya's manufacturing process to support the development of more cost-effective AAV gene therapies. The forward-looking statements contained herein are based upon Tenaya's current expectations and involve assumptions that may never materialize or may prove to be incorrect. These forward-looking statements are neither promises nor guarantees and are subject to a variety of risks and uncertainties, including but not limited to: availability of data at the referenced times; risks associated with the process of discovering, developing and commercializing therapies that are safe and effective for use as human therapeutics; Tenaya's ability to develop, initiate or complete preclinical studies and clinical trials, and obtain approvals, for any of its product candidates; Tenaya's continuing compliance with applicable legal and regulatory requirements; Tenaya's ability to raise any additional funding it will need to continue to pursue its business and product development plans; Tenaya's reliance on third parties; Tenaya's manufacturing, commercialization and marketing capabilities and strategy; the loss of key scientific or management personnel; competition in the industry in which Tenaya operates; Tenaya's ability to obtain and maintain intellectual property protection for its product candidates; general economic and market conditions; and other risks. Information regarding the foregoing and additional risks may be found in the section entitled 'Risk Factors' in documents that Tenaya files from time to time with the Securities and Exchange Commission. These forward-looking statements are made as of the date of this press release, and Tenaya assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Contact Michelle Corral VP, Corporate Communications and Investor Relations Tenaya Therapeutics [email protected] Investors AnneMarie Fields Stern IR [email protected] Media Wendy Ryan Ten Bridge Communications [email protected]
Yahoo
13-05-2025
- Business
- Yahoo
Tenaya Therapeutics to Highlight Capsid Engineering, Gene Editing and Manufacturing Research at the ASGCT 28th Annual Meeting
Advancements Lay the Groundwork for Future Genetic Medicines for Rare and Prevalent Forms of Heart Disease SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it will present five abstracts at the upcoming American Society of Gene and Cell Therapy (ASGCT 2025) 28th Annual Meeting taking place May 13-17, 2025 in New Orleans, LA. The abstracts being presented at ASGCT 2025 capture the outcome of efforts to advance Tenaya's core capabilities in novel capsid engineering, identification, design and optimization of cardiomyocyte-targeting genetic medicines, and manufacturing of adeno-associated virus (AAV) gene therapies. Abstract highlights : Building on previous research that showed the superior cardiomyocyte-targeting and robust transduction attributes of AAV serotype 9 (AAV9) compared to other naturally occurring capsids, Tenaya's researchers combined high throughput in vivo experimental screening with multiple in silico screening tools to efficiently identify various novel capsid candidates. Novel capsids were then compared to one another and to AAV9 in murine and non-human primate models. Select top performing capsids were further evaluated and found to outperform AAV9 in terms of cardiomyocyte targeting and efficient in vivo cardiac gene therapy. Tenaya researchers will share efforts to develop prime editing, a precision gene editing technique, aimed at cardiomyocytes. The machinery required for prime editing exceed the capacity of a single AAV capsid, so Tenaya researchers created a prototype utilizing one of the company's engineered AAV capsids, a dual cassette arrangement delivered via two AAV capsids, and cardiomyocyte-specific regulatory elements. The therapeutic potential of this prime editing prototype was studied in an RBM20 murine model of DCM. The prime editing prototype successfully achieved correction of the mutated RBM20 allele, improving cardiac function and reversing disease in the mouse model. A humanized mouse model of RBM20-mutant DCM was also developed and validated by Tenaya researchers. Testing of the prototype in this model demonstrated effective cardiac editing of the humanized allele using the in vivo dual vector prime editing approach. : Tenaya previously presented research on the development of a Cas9 gene editing therapy, TN-501, designed to specifically inactivate the mutant phospholamban (PLN)-R14del allele, and thereby eliminate the "poison peptide" effects of the mutant protein while preserving wild-type function. Preclinical studies in murine models demonstrated that a low dose of a murine surrogate of TN-501 effectively prevented mutant PLN protein aggregation, reduced cardiac fibrosis, improved cardiac function, and significantly enhanced survival to wild-type levels. Doses tested were well tolerated and anti-Cas9 antibody responses and Cas9 T-cell activation were low. Tenaya successfully established Sf9/rBV-based manufacturing processes at the 1000L scale for its clinical-stage AAV gene therapy programs and subsequently also established a proprietary HEK293-based manufacturing process. Tenaya's HEK393 process utilizes a single plasmid expression system, as well novel transfection reagents, to improve overall yield while lowering overall costs compared to current commercially available options, which may support the development of more cost-effective AAV gene therapies. Details of Tenaya's ASGCT 2025 presentations are as follows: Tuesday, May 13, 2025Poster Abstract Session - 6:00 pm – 7:30 pm Abstract: #523Title: A Humanized RBM20 Mouse Model Exhibits Dilated Cardiomyopathy Phenotypes and Enables Development of In Vivo Prime Editing for Treating Human RBM20 Cardiomyopathy PatientsPresenting author: Wenjing Liang, Ph.D., Scientist Abstract: #952Title: High Productivity HEK293 AAV Production Platform Enabled by Novel Transfection Reagents and Proprietary Plasmid Expression SystemsPresenting author: Charles Feathers, Senior Manager, Process Development Wednesday, May 14, 2025Poster Abstract Session – 5:30 pm – 7:30 pm Abstract: #1022Title: TN-501 Gene Editing Therapy for PLN-R14del-Associated CardiomyopathyPresenting author: Huanyu Zhou, Ph.D., Associate Director Abstract: #1028Title: Developing In Vivo Prime Editing as a Potential Treatment Option for Heart DiseasePresenting author: Lindsey Rollosson, Research Associate II Abstract: #1396 Title: Engineering Novel AAV Capsids for Cardiac Gene DeliveryPresenting author: Ze Cheng, Ph.D., Principal Scientist Following the conference, Tenaya's presentations will be available in the 'Our Science' section of the company's website. About Tenaya TherapeuticsTenaya Therapeutics is a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver potentially curative therapies that address the underlying drivers of heart disease. Tenaya employs a suite of integrated internal capabilities, including modality agnostic target validation, capsid engineering and manufacturing, to generate a portfolio of genetic medicines aimed at the treatment of both rare genetic disorders and more prevalent heart conditions. Tenaya's pipeline includes TN-201, a gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM), TN-401, a gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC), TN-301, a small molecule HDAC6 inhibitor intended for heart failure with preserved ejection fraction (HFpEF), and multiple early-stage programs in preclinical development. For more information, visit Forward-Looking StatementsThis press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Words such as 'will,' 'potential,' 'may,' and similar expressions are intended to identify forward-looking statements. Such forward-looking statements include, among other things, the presentation of data covering Tenaya's capabilities in novel capsid engineering, identification, design and optimization of cardiomyocyte-targeting genetic medicines, and manufacturing of AAV gene therapies; the therapeutic potential of Tenaya's prime editing technology in a humanized RBM20 murine model of DCM; TN-501 as a potential treatment for PLN R14del-associated DCM; the commercial potential of Tenaya's manufacturing process to support the development of more cost-effective AAV gene therapies. The forward-looking statements contained herein are based upon Tenaya's current expectations and involve assumptions that may never materialize or may prove to be incorrect. These forward-looking statements are neither promises nor guarantees and are subject to a variety of risks and uncertainties, including but not limited to: availability of data at the referenced times; risks associated with the process of discovering, developing and commercializing therapies that are safe and effective for use as human therapeutics; Tenaya's ability to develop, initiate or complete preclinical studies and clinical trials, and obtain approvals, for any of its product candidates; Tenaya's continuing compliance with applicable legal and regulatory requirements; Tenaya's ability to raise any additional funding it will need to continue to pursue its business and product development plans; Tenaya's reliance on third parties; Tenaya's manufacturing, commercialization and marketing capabilities and strategy; the loss of key scientific or management personnel; competition in the industry in which Tenaya operates; Tenaya's ability to obtain and maintain intellectual property protection for its product candidates; general economic and market conditions; and other risks. Information regarding the foregoing and additional risks may be found in the section entitled 'Risk Factors' in documents that Tenaya files from time to time with the Securities and Exchange Commission. These forward-looking statements are made as of the date of this press release, and Tenaya assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Contact Michelle CorralVP, Corporate Communications and Investor RelationsTenaya TherapeuticsIR@ InvestorsAnneMarie FieldsStern IR MediaWendy RyanTen Bridge Communicationswendy@
Yahoo
28-03-2025
- Business
- Yahoo
Is Tenaya Therapeutics, Inc. (TNYA) the Cheapest Stock Insiders Are Buying In March?
We recently published a list of . In this article, we are going to take a look at where Tenaya Therapeutics, Inc. (NASDAQ:TNYA) stands against other cheapest stocks insiders are buying in March. After solid gains Monday, the broader market index and blue chip companies traded flat Tuesday, while the NASDAQ Composite rose 0.2%. Monday's enthusiasm came from hopes of looser U.S. tariffs. Investors mostly ignored the March consumer confidence data released on Tuesday, which showed a sharp decline in U.S. consumers' short-term outlook on income, business, and job conditions, reports CNBC. 'Sentiment continues to wane among investors, consumers and businesses as economic concerns and economic policy uncertainty takes its toll,' said Bret Kenwell, U.S. investment analyst at eToro. 'Until there's more certainty on the tariff and macro front, sentiment and confidence remain vulnerable.' As investors navigate daily market changes, uncertainty remains a persistent factor. Insider trading tends to attract attention during these periods, as purchases of company stock by executives may suggest optimism about the company's future. However, insider selling doesn't necessarily signal a lack of confidence—it could simply be for personal financial reasons or to diversify holdings. Many executives use pre-established plans, such as 10b5-1, to maintain transparency. While insider trading can provide useful insights, it's important to evaluate it alongside a company's financial stability, broader market trends, and industry dynamics. What are some of the cheapest stocks insiders have been buying this month so far? To find out, we used Insider Monkey's insider trading stock screener, focusing only on stocks where at least two insiders had purchased shares in March. From there, we ranked the 10 stocks with the lowest average price per share. Our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds, focusing on insider trading and stock picks from hedge fund investor newsletters and conferences. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (). With each stock, we note the average price per share of these purchases and the stock's market capitalization. A scientist in a lab holding a test tube of regenerated cells. Market Capitalization: $113.81 million Next on this list of 15 cheapest stocks insiders are buying in March is Tenaya Therapeutics. The South San Francisco, California-based company discovers, develops, and delivers therapies for heart disease in the United States. For the full year 2024, Tenaya Therapeutics reported a net loss of $111.1 million, or $1.31 per share, compared to a net loss of $124.08 million in 2023. Research and development expenses were $86.7 million, down from $98.0 million the previous year. As of December 31, 2024, the company held $61.4 million in cash, cash equivalents, and marketable securities, a decrease from $104.6 million as of December 31, 2023. With an additional estimated $48.9 million in net proceeds from the March 2025 public offering, Tenaya expects its current funds will be sufficient to support operations through mid-2026. Recently, the company announced positive preclinical results for its gene therapy candidate, TN-201, which targets MYBPC3-associated hypertrophic cardiomyopathy (HCM), a common genetic cause of heart disease. TN-201 is designed to deliver a working MYBPC3 gene to heart cells, increasing the MyBP-C protein to help treat or even reverse the disease. Preclinical data showed that TN-201 improved heart function and reversed key symptoms of HCM, such as thickening of the heart's left ventricle. The therapy is now being tested in a clinical trial, MyPEAK-1, at higher doses. This month, two insiders bought nearly $50 million worth of Tenaya Therapeutics shares at an average price of $0.70 per share. Currently, the stock trades at $0.70, having declined 51.05% year-to-date and 85.60% over the past 12 months. According to TipRanks, seven analysts have given an average 'Buy' rating to Tenaya Therapeutics stock with a price target of $6.25 per share. The average price target suggests a potential upside of 792.86% from the latest price. Additionally, Tenaya is one of the 13 penny stocks with insider buying in 2024. Overall, TNYA ranks 7th on our list of cheapest stocks insiders are buying in March. While we acknowledge the potential of TNYA our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than TNYA but that trades at less than 5 times its earnings, check out our report about the . READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
24-03-2025
- Business
- Yahoo
Tenaya Therapeutics, Inc.'s (NASDAQ:TNYA) stock price dropped 13% last week; individual investors would not be happy
Significant control over Tenaya Therapeutics by individual investors implies that the general public has more power to influence management and governance-related decisions A total of 25 investors have a majority stake in the company with 49% ownership Recent sales by insiders A look at the shareholders of Tenaya Therapeutics, Inc. (NASDAQ:TNYA) can tell us which group is most powerful. With 49% stake, individual investors possess the maximum shares in the company. In other words, the group stands to gain the most (or lose the most) from their investment into the company. And following last week's 13% decline in share price, individual investors suffered the most losses. Let's delve deeper into each type of owner of Tenaya Therapeutics, beginning with the chart below. Check out our latest analysis for Tenaya Therapeutics Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing. As you can see, institutional investors have a fair amount of stake in Tenaya Therapeutics. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Tenaya Therapeutics, (below). Of course, keep in mind that there are other factors to consider, too. Hedge funds don't have many shares in Tenaya Therapeutics. Our data shows that The Column Group, LLC is the largest shareholder with 30% of shares outstanding. With 4.1% and 3.3% of the shares outstanding respectively, Casdin Capital, LLC and BlackRock, Inc. are the second and third largest shareholders. On studying our ownership data, we found that 25 of the top shareholders collectively own less than 50% of the share register, implying that no single individual has a majority interest. Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too. The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO. Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances. Our information suggests that Tenaya Therapeutics, Inc. insiders own under 1% of the company. It has a market capitalization of just US$104m, and the board has only US$639k worth of shares in their own names. We generally like to see a board more invested. However it might be worth checking if those insiders have been buying. The general public-- including retail investors -- own 49% stake in the company, and hence can't easily be ignored. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies. With a stake of 30%, private equity firms could influence the Tenaya Therapeutics board. Some investors might be encouraged by this, since private equity are sometimes able to encourage strategies that help the market see the value in the company. Alternatively, those holders might be exiting the investment after taking it public. While it is well worth considering the different groups that own a company, there are other factors that are even more important. Consider for instance, the ever-present spectre of investment risk. We've identified 3 warning signs with Tenaya Therapeutics , and understanding them should be part of your investment process. But ultimately it is the future, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
